DGX Stock Recent News

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks?

Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.

Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards SECAUCUS, N.J. , Oct. 23, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been awarded several contracts by the U.S. Centers for Disease Control and Prevention (CDC) to support testing and sustained laboratory readiness for two emerging infectious diseases recently identified in people in the Americas.

One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.

Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Michael Cherny - Leerink Partners Patrick Donnelly - Citi Pito Chickering - Deutsche Bank Meghan Holtz - Jefferies David Westenberg - Piper Sandler Jack Meehan - Nephron Research Elizabeth Anderson - Evercore ISI Erin Wright - Morgan Stanley Stephanie Davis - Barclays Lisa Gill - JP Morgan Andrew Brackmann - William Blair Kevin Caliendo - UBS Michael Riskin - Bank of America Operator Welcome to the Quest Diagnostics Third Quarter 2024 conference call. At the request of the company, this call is being recorded.

Quest Diagnostics Inc  DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.

Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.

Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.